22:
335:(tubercular bacillus isolated from turtles) into animals significantly increased their resistance to infections. The isolation of the active ingredient of this bacterium, entrusted to Tsehay Neway, made it possible to isolate a polar glycopeptidolipid (GPLP). This substance has shown significant activity on immune cells. This immunostimulant acting on
143:
Charles Pilet was elected a member of the French
Academy of Medicine in 1983 and chaired the Academy in 1999. His presidency will be marked by several important reforms, in particular concerning the governance of the Academy (modification of the role of the Board of Directors), the recognition of the
286:
silence that is most often observed in this phase of the disease. Given the essentially cellular nature of brucella immunity, Charles Pilet and his team proposed replacing the traditional serodiagnosis with a cellular test. This new diagnostic possibility led the microbiology laboratory at the École
316:
The dogma of the time that the newborn animal or human being was tolerant to a foreign substance was in fact only partially accurate. Work on immune tolerance had previously been conducted with soluble antigens. Using a particulate antigen extracted from
Brucella, Charles Pilet and his team showed
144:
truly national character of the institution thanks to the abolition of the "non-resident section", the implementation of a communication adapted to the needs of the time, the promotion of the corresponding members, and the presence of the
President of the Republic at the Academy in November 1999.
469:
640:
Ch.Pilet, Y.Legarrec, « Contrôle sur petits animaux de laboratoire du pouvoir immunogène des vaccins antibrucelliques inactivés. I. Sur le choix des espèces animales et de l’époque du sacrifice lors du contrôle du pouvoir immunogène par le test de l’infection »,
109:
de Paris (1955); Assistant (1956), Head of Works (1957) at the École nationale vétérinaire d'Alfort, Charles Pilet graduated from the École nationale vétérinaire d'Alfort in 1960 and was appointed Head of
Department in 1964. He was appointed Full Professor of
268:. This vaccine did not develop agglutinating antibodies. This property made it possible to distinguish infected animals (carriers of agglutinating antibodies) from vaccinated animals (not carriers of this type of antibody) and thus to facilitate disease
676:
Ch.Pilet, Y.Legarrrec, « Contrôle sur petits animaux de laboratoire du pouvoir immunogène des vaccins antibrucelliques inactivés. III.Sur l’opportunité de la conservation à basse température des organes infectés avant ensemencement »,
658:
Ch.Pilet,Y. Legarrec, « Contrôle sur petits animaux de laboratoire du pouvoir immunogène de vaccins antibrucelliques inactivés. II. Sur les modalités de traitement avant ensemencement des organes infectés. Résultats et conséquences »,
206:
Member of the High
Council of Universities totally or partially French-speaking (1988). Charles Pilet founded the Association des établissements vétérinaires totalement ou partiellement de langue française and the Association des vétérinaire
228:
After a series of studies, at the beginning of his career, on several animal disease viruses, some of which were suspected at the time of being transmissible to humans, Charles Pilet directed his research towards the immunology of
790:
B.Gjata,C.Hannoun,C.Boulouis,T.Neway, Ch. Pilet, « Adjuvant activity of polar glycopeptidolipids of
Mycobacterium chelonae (pGPL-MC) on the immunogenic and protective effects of an inactivated influenza vaccine »,
317:
that in this case, the newborn mouse could respond very early to antigenic solicitation. This lack of immune tolerance is probably due to the non-specific activity of
Brucella's particulate extracts on the maturation of the
763:
Lagrange, P. H.; Fourgeaud, M.; Neway, T.; Pilet, C. (1994). "Enhanced resistance against lethal disseminated
Candida albicans infection in mice treated with polar glycopeptidolipids from Mycobacterium chelonae (PGPL-Mc)".
150:
Charles Pilet is also a member of the French
Academy of Technologies (2000). It also belongs to the Romanian Academy of Scientists, the Spanish Academy of Veterinary Sciences and the Italian Society of Veterinary Sciences.
129:
in 1984, the effective commissioning of a clinical application antenna in the provinces, the construction of two new buildings, and the doubling of the number of students over four years ("double promotions").
178:
Member of the committee in charge of drafting the environmental charter (2003) (Ch. Pilet was one of the members of this committee who opposed the inclusion of the precautionary principle in the constitution.)
172:
Head of the network responsible for preparing the French scientific project for the second meeting of Heads of State and
Government sharing the French language (second Francophone summit; Quebec 1987)
166:
Member of the National Research Evaluation Committee (CNER) (1997-2003) He is the initiator within CNER of the report entitled "Research on animals and human health" (Documentation française.2003)
728:
Ch.Pilet, Y.Legarrec,L.Toujas, D.Sabolovic, J.C.Monteil, F.Rothier, U.Mishra, G.Ghebrehinet, J. Guelfi, « Non specific stimulation by inactivated or ultrasonicated Brucella abortus »,
623:
J.M. Person, J. Frottier, Y. Legarrec, F. Barrat, R. Bastin, Ch.Pilet, « Exploration of the cellular mediated immunity by the blastogenesis test during chronic brucellosis in human »,
121:
His time at the Alfort School was marked by the development of the School's international relations, the creation of the Institute of Animal and Comparative Immunology (1981) recognized by the
118:
at the École Nationale Vétérinaire d'Alfort in 1967. He became director of this school in 1975, and was re-elected and reappointed to this position for a further five-year term in 1980.
745:
T.Neway, F,Barrat, J.M.Person,H.J.Boulouis, Ch.Pilet, « Immunomodulatory properties of a strain of Mycobacterium chelonae. I. Mouse lymphocytic responses in vitro »,
897:
329:
This observation relating to immune tolerance, as well as a clinical observation, led to a new direction in Charles Pilet's work. It had been noted that the injection of
443:
90:
126:
169:
President of the CAMPUS Committee (Cooperation with Africa and Madagascar for Academic and Scientific Promotion at the Ministry of Cooperation). (1987-1997)
187:
In charge of the French government's implementation of France's assistance to Tunisia for the establishment of the Tunisian Veterinary School. (1974-1980)
606:
Ch.Pilet, J.M.Person, J.Frottier, R.Bastin, F.Barrat, « Test de transformation lymphoblastique et diagnostic des brucelloses chroniques »,
711:
Ch.Pilet, B.Mallick, « Sur l’absence de tolérance immunitaire du souriceau nouveau-né vis à vis d’un complexe antigénique brucellique »,
429:
694:
Ch.Pilet, Y. Legarrec, « Contrôle sur petits animaux de laboratoire du pouvoir immunogène des vaccins antibrucelliques inactivés »,
497:
589:
Ch.Pilet ,M.A. Shalaby, J.M.Person, « Etude préliminaire du vaccin antibrucellique PB REV1,destiné aux espèces ovine et caprine »,
483:
303:, which made it possible to propose a new method for controlling brucella vaccines, a method that has since been adopted internationally.
82:
353:. Unfortunately, the synthesis of this product of biological origin has proved too expensive to allow human trials to be conducted.
203:
Member and then President of the Association of Veterinary Microbiologists, Immunologists and Infectious Disease Specialists (1977).
837:
902:
385:
272:. This type of vaccine also confirmed the essentially cellular nature of brucella immunity and the passive role of antibodies.
365:
Ch.Pilet, J.L.Bourdon, B.Toma, N.Marchal, C.Balestre, JL.Person. Bactériologie médicale et vétérinaire. Edit: In 1981 and 1989
137:" in 1978 (Ed : Pergamon, then Elsevier) and remained editor-in-chief until the end of his teaching and research duties.
538:
Ch.Pilet, M.Bonneau, L.Valette, « Etude préliminaire et comparée du vaccin antibrucellique P.B. chez les bovins »,
86:
447:
892:
887:
147:
Elected corresponding member of the French Academy of sciences in 1990, he became a full member of this company in 2005.
391:
823:
78:
122:
321:, which becomes able to respond to specific antigenic stimulation much earlier by a classical immune response.
809:
907:
331:
572:
M.Bonneau, L.Valette, Ch.Pilet, « Complexe antigène-anticorps et immunité antibrucellique »,
882:
501:
350:
184:
President of the Scientific Council of the Louis Mallardé Institute (Papeete, Polynesia 2001- 2007)
32:
74:
773:
106:
523:
International symposium on Brucellosis Tunis 1968. Series immunobiol.Standard. (Karger,Basel)
862:
521:
Ch.Pilet, M.Bonneau, « Sur un nouveau vaccin antibrucellique non agglutinogène »,
379:
309:
287:
d'Alfort to receive numerous requests for examinations from Parisian hospitals at the time.
256:
140:
Elected member of the Académie vétérinaire de France in 1977, he became president in 1988.
555:
Ch.Pilet, M.Bonneau, L.Valette, « Nouveau type de vaccin non agglutinogène »,
841:
876:
362:
Ch. Pilet, J.L. Bourdon, N. Marchal. Le laboratoire de bactériologie. Edit: Doin 1972
346:
343:
318:
51:
102:
299:
The study of several mouse lines showed the sensitivity of some of these lines to
397:
336:
269:
430:"Comparative immunology, microbiology and infectious diseases_ Editorial Board"
175:
Member of the Medical Board of Électricité de France/ Gaz de France (2001-2007)
111:
101:
Student at the École nationale vétérinaire de Lyon (1950-1954), a graduate in
339:
163:
President of the French Committee of the World Veterinary Association (1985)
115:
41:
21:
777:
368:
Charles Pilet and Nicole Priollaud. L’Animal médecin Edit : Actes Sud
283:
265:
230:
470:"Usine nouvelle-Ch Pilet, Président de l'Académie nationale de médecine"
409:
403:
261:
251:
197:
Expert on European Pharmacopoeia at the Council of Europe (1970-1995)
282:
The diagnosis of chronic human brucellosis is made difficult by the
200:
President of the 15V Group of the European Pharmacopoeia (1975-1995)
213:
Co-Chairman of the Franco-Japanese Society of Veterinary Sciences.
73:, born in February 1931, is a professor-researcher, member of the
210:
Vice-President of the World Veterinary Association (1991-1999)
15:
349:
and was able to correct immunosuppression in mice caused by
250:
Charles Pilet and Marc Bonneau are creating a new type of
135:
Comparative Immunology Microbiology and Infectious Disease
46:
36:
160:
Member of the National Pharmacopoeia Commission (1970)
85:
and the Académie vétérinaire de France, member of the
766:
Comptes Rendus de l'Académie des Sciences, Série III
557:
C.R.Congrès international de microbiologie de Mexico
396:
Commandeur of the National Order of the Republic of
233:, which then led him to focus on immunostimulation.
408:Officier of the Order of Merit of the Republic of
219:Adviser for veterinary education in Tunisia (1976)
89:, Professor Emeritus and Honorary Director of the
260:made non-agglutinogenic by saturating peripheral
216:Advisor for veterinary research in Tunisia (1975)
540:Symp. Series. Immunobio. Standard (Karger Basel)
133:Charles Pilet created the scientific journal "
574:Symp.Series immunobio Standard (Karger-Basel)
8:
181:Expert at the Paris Cour d'Appel (1975-2001)
155:Other responsibilities at the national level
898:Members of the French Academy of Sciences
402:Officier of the Order of the Republic of
824:"Bactériologie médicale et vétérinaire"
421:
468:Nouvelle, L'Usine (9 September 1999).
7:
192:Other international responsibilities
91:École nationale vétérinaire d'Alfort
292:An improved vaccine control method
14:
810:"Le laboratoire de bactériologie"
747:Comp.Immun.Microbiol.Infect.Dis.
696:Symp. Series Immunobio. Standard
625:Comp.Immun.Microbiol.Infect.Dis.
444:"Académie vétérinaire de France"
20:
591:Comp.Immun.Microbiol.Infect.Dis
87:French Academy of technologies
1:
81:, Honorary President of the
498:"Académie des technologies"
924:
83:French Academy of medicine
79:French Academy of sciences
123:World Health Organization
715:, 264 ,serie iii, 1967,
127:WHO collaborating centre
484:"Académie des sciences"
277:A new diagnostic method
35:, as no other articles
903:French microbiologists
332:Mycobacterium chelonae
237:Immunology of Brucella
243:A new type of vaccine
893:French immunologists
888:French veterinarians
608:Bull.Acad.Natle.Med.
351:cancer chemotherapy
863:"LĂ©gion d'honneur"
838:"L'animal médecin"
386:Palmes Académiques
384:Commandeur of the
378:Commandeur of the
308:A new approach to
75:Institut de France
54:for suggestions.
44:to this page from
772:(12): 1107–1113.
679:Ann.Inst. Pasteur
325:Immunostimulation
254:from a strain of
116:General Pathology
68:
67:
915:
867:
866:
859:
853:
852:
850:
849:
840:. Archived from
834:
828:
827:
820:
814:
813:
806:
800:
798:
788:
782:
781:
760:
754:
752:
743:
737:
735:
726:
720:
718:
709:
703:
701:
692:
686:
684:
674:
668:
666:
661:Ann.Inst.Pasteur
656:
650:
648:
643:Ann.Inst.Pasteur
638:
632:
630:
621:
615:
613:
610:, 167,(8) 1983,
604:
598:
596:
587:
581:
579:
570:
564:
562:
553:
547:
545:
536:
530:
528:
519:
513:
512:
510:
509:
500:. Archived from
494:
488:
487:
480:
474:
473:
465:
459:
458:
456:
455:
446:. Archived from
440:
434:
433:
426:
380:LĂ©gion d'Honneur
342:was also a true
310:immune tolerance
301:Brucella abortus
257:Brucella abortus
107:Institut Pasteur
77:, member of the
63:
60:
49:
47:related articles
24:
16:
923:
922:
918:
917:
916:
914:
913:
912:
873:
872:
871:
870:
861:
860:
856:
847:
845:
836:
835:
831:
822:
821:
817:
808:
807:
803:
796:
793:C.R. Acad. Sci.
789:
785:
762:
761:
757:
750:
749:, 12,(3) 1989,
744:
740:
733:
727:
723:
716:
710:
706:
699:
693:
689:
682:
675:
671:
664:
657:
653:
646:
639:
635:
628:
622:
618:
611:
605:
601:
594:
588:
584:
577:
571:
567:
560:
554:
550:
543:
537:
533:
526:
520:
516:
507:
505:
496:
495:
491:
482:
481:
477:
467:
466:
462:
453:
451:
442:
441:
437:
428:
427:
423:
418:
392:MĂ©rite Agricole
375:
359:
327:
266:immunoglobulins
239:
226:
224:Scientific work
194:
157:
99:
64:
58:
55:
45:
42:introduce links
25:
12:
11:
5:
921:
919:
911:
910:
905:
900:
895:
890:
885:
875:
874:
869:
868:
854:
829:
815:
801:
783:
755:
738:
721:
704:
687:
669:
651:
633:
616:
599:
582:
565:
548:
531:
514:
489:
475:
460:
435:
420:
419:
417:
414:
413:
412:
406:
400:
394:
388:
382:
374:
371:
370:
369:
366:
363:
358:
355:
326:
323:
314:
313:
297:
296:
280:
279:
264:with specific
248:
247:
238:
235:
225:
222:
221:
220:
217:
214:
211:
208:
204:
201:
198:
193:
190:
189:
188:
185:
182:
179:
176:
173:
170:
167:
164:
161:
156:
153:
98:
95:
66:
65:
52:Find link tool
28:
26:
19:
13:
10:
9:
6:
4:
3:
2:
920:
909:
908:Living people
906:
904:
901:
899:
896:
894:
891:
889:
886:
884:
881:
880:
878:
864:
858:
855:
844:on 2019-04-04
843:
839:
833:
830:
825:
819:
816:
811:
805:
802:
795:, 317, 1994,
794:
787:
784:
779:
775:
771:
767:
759:
756:
748:
742:
739:
731:
725:
722:
714:
708:
705:
697:
691:
688:
681:, 112, 1967,
680:
673:
670:
663:, 112, 1967,
662:
655:
652:
645:, 110, 1966,
644:
637:
634:
626:
620:
617:
609:
603:
600:
593:, 3-4, 1981,
592:
586:
583:
575:
569:
566:
558:
552:
549:
541:
535:
532:
524:
518:
515:
504:on 2019-04-04
503:
499:
493:
490:
485:
479:
476:
471:
464:
461:
450:on 2019-04-04
449:
445:
439:
436:
431:
425:
422:
415:
411:
407:
405:
401:
399:
398:CĂ´te d'Ivoire
395:
393:
390:Chevalier of
389:
387:
383:
381:
377:
376:
372:
367:
364:
361:
360:
356:
354:
352:
348:
347:growth factor
345:
344:hematopoietic
341:
338:
334:
333:
324:
322:
320:
319:immune system
312:
311:
306:
305:
304:
302:
295:
293:
290:
289:
288:
285:
278:
275:
274:
273:
271:
267:
263:
259:
258:
253:
246:
244:
241:
240:
236:
234:
232:
223:
218:
215:
212:
209:
207:francophones.
205:
202:
199:
196:
195:
191:
186:
183:
180:
177:
174:
171:
168:
165:
162:
159:
158:
154:
152:
148:
145:
141:
138:
136:
131:
128:
124:
119:
117:
113:
110:Microbiology-
108:
104:
96:
94:
92:
88:
84:
80:
76:
72:
71:Charles Pilet
62:
53:
48:
43:
39:
38:
34:
29:This article
27:
23:
18:
17:
857:
846:. Retrieved
842:the original
832:
818:
804:
792:
786:
769:
765:
758:
746:
741:
732:, 47, 1974,
729:
724:
713:C.R.Acad.Sci
712:
707:
698:, 10, 1969,
695:
690:
678:
672:
660:
654:
642:
636:
627:, 10, 1987,
624:
619:
607:
602:
590:
585:
573:
568:
556:
551:
542:, 12, 1970,
539:
534:
525:, 12, 1970,
522:
517:
506:. Retrieved
502:the original
492:
478:
463:
452:. Retrieved
448:the original
438:
424:
373:Distinctions
330:
328:
315:
307:
300:
298:
294:
291:
281:
276:
255:
249:
245:
242:
227:
149:
146:
142:
139:
134:
132:
120:
103:microbiology
100:
70:
69:
56:
30:
883:1931 births
730:Cancer Res.
576:, 5, 1972,
337:bone marrow
284:serological
270:prophylaxis
877:Categories
848:2019-12-13
508:2019-12-13
454:2019-12-13
416:References
357:Some works
340:stem cells
112:Immunology
50:; try the
37:link to it
719:1818-1821
105:from the
59:July 2020
40:. Please
559:, 1970,
262:antigens
231:Brucella
799:257-263
778:7697466
736:294-301
702:125-140
685:516-520
667:384-388
649:755-765
614:845-848
597:255-265
580:537-541
410:Senegal
404:Tunisia
252:vaccine
776:
97:Course
33:orphan
31:is an
753:63-70
563:88-92
546:63-68
529:53-62
125:as a
774:PMID
770:317
631:1-8
879::
797:p.
768:.
751:p.
734:p.
717:p.
700:p.
683:p.
665:p.
647:p.
629:p.
612:p.
595:p.
578:p.
561:p.
544:p.
527:p.
114:,
93:.
865:.
851:.
826:.
812:.
780:.
511:.
486:.
472:.
457:.
432:.
61:)
57:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
